Background
Methods
Information sources
Definitions & Eligibility criteria
Search strategy | # Treatable CP mimics | ||
---|---|---|---|
1) PubMed search using combinations of alternative terms to describe the CP phenotype and IEMs | Definition: | Search terms: | 27 |
Cerebral palsy | Cerebral palsy, spastic, spasticity, dystonia, dyskinesia, ataxia, movement disorder, gait abnormalities, hypoxic(+/−ischemic) encephalopathy, perinatal asphyxia | ||
Inborn error of metabolism | Inborn error of metabolism, metabolic disease, amino acids, creatine, mitochondria, neurotransmitter, organic acid, urea cycle, vitamins | ||
2) Manual search | Reference lists of articles identified through PubMed search were manually screened for additional citations. | 15 | |
3) Targeted search of known treatable IEMs causing ID | Diseases listed in the TIDE App (www.treatable-id.org) as treatable IEMs searched in combination with the above IEM search terms. | 12 | |
Total number of IEMs identified | 54 |
Search strategy
Data collection
Characterizing treatment & effects
Levels of evidence
Expert-identified CP mimics
Diagnostic algorithm
Results
Treatable IEMs
Biochemical category | Disease name | OMIM# | Gene(s) | Treatment | Effect | Level of evidence | CP symptoms |
---|---|---|---|---|---|---|---|
Amino acids | Hartnup disease | 234500 |
SLC6A19 (AR)
| High protein diet | Stabilizing/preventative treatment | 4-5 | Dystonia |
Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome | 238970 |
SLC25A15 (AR)
| Dietary protein restriction, ornithine supplement, sodium benzoate, phenylacetate | Stabilizing/preventative treatment | 4 | Spasticity | |
Late onset non-ketotic hyperglycinemia | 605899 |
AMT/GLDC/GCSH (AR)
| Glycine restriction, +/− sodium benzoate, NMDA receptor antagonists, other neuromodulating agents | Stabilizing/preventative treatment | 4-5 | Spastic diplegia | |
Phenylketonuria (PKU) | 261600 |
PAH (AR)
| Dietary phenylalanine restriction +/− amino acid supplements (BH(4) supplement) | Stabilizing/preventative treatment | 2a (4) | Spastic diplegia | |
PHGDH deficiency (Serine deficiency) | 601815 |
PHGDH (AR)
| L-serine & +/−glycine supplements | Primary/targeting underlying pathophysiology | 4 | Spastic diplegia/tetraparesis | |
Cerebral glucose transport | Blood brain-barrier glucose-transporter (GLUT1) defect | 606777 |
SLC2A1 (AR)
| Ketogenic diet | Primary/targeting underlying pathophysiology | 4 | Spasticity, dystonia, ataxia |
Creatine | GAMT deficiency | 612736 |
GAMT (AR)
| Arginine restriction, creatine & ornithine supplements | Primary/targeting underlying pathophysiology | 4 | Movement disorder: extrapyramidal signs, athetosis, & ataxia |
Fatty acid oxidation | Medium-chain acyl-coenzyme A dehydrogenase (MCAD) deficiency | 201450 |
ACADM (AR)
| Emergency regimen, L-carnitine, avoid fasting | Stabilizing/preventative treatment | 2a | CP symptoms |
Short-chain acyl-CoA dehydrogenase (SCAD) deficiency | 201470 |
ACADS (AR)
| Emergency regimen, L-carnitine | Stabilizing/preventative treatment | 2c | Spastic diplegia | |
Very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency | 201475 |
ACADVL (AR)
| Avoidance of fasting, low-fat diet, Medium Chain Triglyceride oild | Stabilizing/preventative treatment | 4 | Neonatal asphyxia | |
Hyperhomo-cysteinemia | Homocystinuria due to Cystathionine β-synthase deficiency | 236200 |
CBS (AR)
| Methionine restriction, +/− pyridoxine, +/− betaine | Stabilizing/preventative treatment | 2c | Dystonia |
MTHFR deficiency | 236250 |
MTHFR (AR)
| Betaine supplements, +/− folate, carnitine, methionine supplements | Stabilizing/preventative treatment | 4 | Ataxic gait, hypotonia, extrapyramidal movements, upper motor neuron signs | |
Lipids | Abetalipoproteinemia | 200100 |
MTTP (AR)
| Low long-chain fatty acid diet with fat-soluble vitamin (i.e., A, D, E, K) supplementation | Primary/targeting underlying pathophysiology | 4 | Ataxia, abnormal gait |
Lysosomal | Fucosidosis | 230000 |
FUCA1 (AR)
| Haematopoietic stem cell transplant | Stabilizing/preventative treatment | 5 | Severe spasticity; spastic paresis, generalized dystonia |
Krabbe disease | 245200 |
GALC (AR)
| Haematopoietic stem cell transplant | Stabilizing/preventative treatment | 2c | Progressive spasticity | |
Metachromatic leucodystrophy (MLD) | 250100 |
ARSA (AR)
| Haematopoietic stem cell transplant | Stabilizing/preventative treatment | 4-5 | Loss of all gross motor function measured by CP scale; ataxia | |
Neimann-Pick, type C | 257220 |
NPC1, NPC2
| Miglustat | Stabilizing/preventative treatment | 1b | Axial hypotonia, spastic diparesis, dystonic posturing of the hands | |
Metals | Menkes Disease | 309400 |
ATP7A
| Copper histidine | Stabilizing/preventative treatment | 4 | Progressive spasticity, hypotonia |
Wilson Disease | 277900 |
ATP7B
| Zinc & tetrathiomolybdate; oxcarbazepine | Stabilizing/preventative treatment | 1b | Neurological symptoms, dystonia | |
Mitochondria | Coenzyme Q10 deficiency | 607426 |
COQ2, APTX, PDSS1, PDSS2, CABC1, COQ9 (most AR)
| CoQ supplements | Primary/targeting underlying pathophysiology | 4 | Spastic paresis; progressive ataxia and dystonia |
MELAS | 540000 |
mt.A3243G, mt.G13513A (mtDNA)
| Arginine supplements | Stabilizing/preventative treatment | 4-5 | dx. CP | |
Pyruvate dehydrogenase deficiency | 312170, 245348 |
PDHA1 (X-linked recessive), DLAT (AR), PDHX (AR)
| Ketogenic diet & thiamine | Primary/targeting underlying pathophysiology | 4 | Spastic quadriplegia; dystonia | |
Neurotransmission | Aromatic-L-amino-acid decarboxylase deficiency | 608643 |
DDC (AR)
| MAO inhibitors, B6, anti-cholinergics, dopa agonists) | Primary/targeting underlying pathophysiology | 4 | Limb dystonia, athetoid movement |
DHPR deficiency (biopterin deficiency) | 261630 |
QDPR (AR)
| BH4, diet, amine replacement, folinic acid | Primary/targeting underlying pathophysiology | 4 | Ataxia, gait disorder, peripheral spasticity | |
Dopamine transporter deficiency syndrome | 126455 |
SLC6A3
| Dopamine antagonist (Ropinirole) | Primary/targeting underlying pathophysiology | 4 | dx. CP | |
GTPCH1-deficient dopa-responsive dystonia (aka Segawa’s disease) | 233910 |
GCH1 (AR)
| BH4, amine replacement | Primary/targeting underlying pathophysiology | 4 | dx. CP; spastic diplegia | |
PTPS deficiency (biopterin deficiency) | 261640 |
PTS (AR)
| BH4, diet, amine replacement | Primary/targeting underlying pathophysiology | 4 | Dystonia; spastic extremities; generalized dystonia, choreoathetoid arm movements & axial hypotonia | |
Sepiapterin reductase deficiency | 612716 |
SPR (AR)
| Amine replacement | Primary/targeting underlying pathophysiology | 4 | Limb spasticity, dystonic signs; “hypotonic cerebral palsy”; dystonia, axial hypotonia; misdx. CP | |
Succinic semialdehyde dehydrogenase deficiency (SSADH) | 271980 |
ALDH5A1 (AR)
| Vigabatrin | Stabilizing/preventative treatment | 4 | Hypotonia, ataxia; gait clumsiness, dystonia | |
Tyrosine hydroxylase deficiency | 605407 |
TH (AR)
| L-dopa substitution | Primary/targeting underlying pathophysiology | 4 | Spastic paraplegia/tetraparesis | |
Vesicular monoamine transporter 2 (VMAT2) | 193001 |
SLC18A2
| Dopamine aginist | Primary/targeting underlying pathophysiology | 4 | Dystonia | |
Organic acids | β-Ketothiolase deficiency | 203750 |
ACAT1 (AR)
| Avoid fasting, emergency regimen, protein restriction | Stabilizing/preventative treatment | 5 | Ataxia, diplegia, hypotonia |
2-Methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency | 300438 |
HSD17B10 (X-linked)
| Avoid fasting, emergency regimen, isoleucine restricted diet | Stabilizing/preventative treatment | 5 | Ataxia, dystonia, choreoathetosis, spastic di-/tetra-plegia, hypotonia | |
3-Methylcrotonyl-CoA carboxylase (MCC) deficiency | 210200; 210210 |
MCC1/MCC2 (AR)
| Dietary protein restriction; carnitine, glycine, biotin supplements; avoid fasting; emergency regimen | Stabilizing/preventative treatment | 5 | dx. CP | |
3-Methylglutaconic aciduria type 1 | 250950 |
AUH (AR)
| Carnitine supplements, avoid fasting, emergency regimen | Stabilizing/preventative treatment | 5 | dx. CP | |
Ethylmalonic encephalopathy | 602473 |
ETHE1 (AR)
| N-acetylcysteine, oral metronidazol | Stabilizing/preventative treatment | 4 | CNS malformations, episodic ataxia; pyramidal tract signs | |
Glutaric aciduria type I (GA1) aka glutaryl-CoA dehydrogenase deficiency | 231670 |
GCDH (AR)
| Lysine restriction, carnitine supplements | Stabilizing/preventative treatment | 2a | Generalized spasticity, dystonia with athethosis; dx. CP; dyskinesia, dystonic tetraparesis | |
Isovaleric acidemia | 243500 |
IVD (AR)
| Dietary protein restriction, carnitine supplements, avoid fasting, emergency regimen | Stabilizing/preventative treatment | 2c | Hypotonia, paresis | |
Multiple acyl-CoA-dehydrogenase deficiency (MADD) (aka Glutaric aciduria type II) | 231680 |
ETFA, ETFB, ETFDH (AR)
| Carnitine, riboflavin, β-hydroxybutyrate supplements; emergency regimen | Primary/targeting underlying pathophysiology | 5 | Encephalopathy | |
Maple syrup urine disease | 248600 |
DBT, BCKDHB, BCKDHA (AR)
| Dietary restriction, branched amino-acids, avoid fasting, (liver transplantation) | Stabilizing/preventative treatment (liver tx = primary treatment) | 4 (4) | Spastic diplegic CP; paroxysmal dystonia; ataxia | |
Methylmalonic acidemia (mutase deficiency) | 251000 |
MUT (AR)
| Dietary protein restriction, carnitine supplements, avoid fasting, emergency regimen | Stabilizing/preventative treatment | 2c | Total body dystonia | |
Lesch-Nyhan syndrome | 300322 |
HPRT1 (X-linked)
| Haematopoietic stem cell transplant | Primary/targeting underlying pathophysiology | 4-5 | dx. Athetotic/dyskinetic CP; dystonia | |
Propionic acidemia | 606054 |
PCCA, PCCB (AR)
| Dietary protein restriction, carnitine supplements, avoid fasting, emergency regimen | Stabilizing/preventative treatment | 2c | Dystonia, hypotonia | |
Urea cycle | Argininemia | 207800 |
ARG1 (AR)
| Dietary protein restriction, arginine supplement, sodium benzoate, phenylbutyrate (Liver transplantation) | Stabilizing/preventative treatment (liver tx = primary treatment) | 2b (4) | Spastic diplegia, ataxia, dx. CP |
Argininosuccinic aciduria | 207900 |
ASL (AR)
| Low protein diet, arginine-supplements, sodium benzoate, phenylbutyrate (liver transplantation) | Stabilizing/preventative treatment (liver tx = primary treatment) | 2b (4) | Cerebellar ataxia | |
Citrullinemia, type II | 605814 |
SLC25A13 (AR)
| Dietary protein restriction, arginine supplement, sodium benzoate, phenylbutyrate (Liver transplantation) | Stabilizing/preventative treatment (liver tx = primary treatment) | 2b (4) | dx. CP; spastic quadriplegia | |
Ornithine transcarbamylase deficiency | 311250 |
OTC (X-linked)
| Dietary protein restriction, citrulline supplements, sodium benzoate/phenylbutyrate (Liver transplantation) | Stabilizing/preventative treatment (liver tx = primary treatment) | 2b (4) | Hemiplegia; ataxia; gait disturbance | |
Vitamins/Co-factors | Biotinidase deficiency | 2532760 |
BTD (AR)
| Biotin supplement | Primary/targeting underlying pathophysiology | 2c | Spastic tetraparesis |
Biotin-thiamine-responsive basal ganglia disease | 607483 |
SLC19A3 (AR)
| Biotin supplement | Primary/targeting underlying pathophysiology | 4 | Ataxia, dystonia | |
Cerebral folate deficiency syndrome | 613068 |
FOLR1 (AR)
| Folinic acid | Primary/targeting underlying pathophysiology | 4 | spastic paraplegia; perinatal asphyxia | |
Holocarboxylase synthetase deficiency | 253270 |
HLCS (AR)
| Biotin supplement | Primary/targeting underlying pathophysiology | 4 | dx. CP | |
Hypermanganesemia with dystonia, polycythemia, and cirrhosis (HMDPC) | 613280 |
SLC30A10 (AR)
| Chelation therapy | Primary/targeting underlying pathophysiology | 4 | Dystonia | |
Molybdenum cofactor deficiency | 252150 |
MOCS1, MOCS2, (AR)
| Precursor Z/cPMP | Primary/targeting underlying pathophysiology | 4 | Spastic quadriplegia dx. CP | |
Pyridoxamine 5’-phosphate oxidase deficiency | 610090 |
PNPO (AR)
| Pyridoxal 5’-phosphate | Stabilizing/preventative treatment | 4 | Spastic quadriplegia |
Biochemical category | Disease name | OMIM# | Gene(s) | Treatment | Effect | Level of evidence |
---|---|---|---|---|---|---|
Amino acids | PSAT deficiency | 610992 | PSAT1 (AR) | L-serine & +/−glycine supplements | Primary/targeting underlying pathophysiology | 4 |
PSPH deficiency (Serine deficiency) | 614023 | PSPH (AR) | L-serine & +/−glycine supplements | Primary/targeting underlying pathophysiology | 4 | |
Creatine | Arginine:glycine amidinotransferase (AGAT) deficiency | 612718 |
GATM (AR)
| Creatine supplements | Primary/targeting underlying pathophysiology | 4 |
Creatine transporter deficiency | 300352 |
SLC6A8 (X-linked)
| Creatine, glycine, arginine supplements | Primary/targeting underlying pathophysiology | 4 | |
Fatty acid oxidation | Carnitine palmitoyltransferase I deficiency | 255120 | CPT1A (AR) | Low-fat, high carbohydrate diet, avoid fasting, Medium Chain Triglyceride oil | Stablizilng/preventative treatment | 4 |
Hyperhomocystinuria | Cobalamin deficiencies (e.g., C, D, E, F, G) | 251110, 277400, 277410, 236270, 277380 | MMACHC, MMADHC, MTRR, LMBRD1, MTR (AR) | Hydroxy-/cyanocobalamin (+/− diet restriction, betaine, B12) | Stabilizing/preventative treatment | 4 |
Lipid storage (Leukodystrophy) | Cerebrotendinous xanthomatosis (CTX) | 213700 | CYP27A1 (AR) | Chenodeoxycholic acid | Stabilizing/preventative treatment | 4 |
Organic acids | HMG-CoA lyase deficiency | 246450 | HMGCL (AR) | Protein restriction, avoid fasting, emergency regimen | Stabilizing/preventative treatment | 4-5 |
mHMG-CoA synthase deficiency | 605911 | HMGCS2 (AR) | Avoid fasting,emergency regimen, +/−dietary precursor restriction | Stabilizing/preventative treatment | 5 | |
SCOT deficiency | 245050 | OXCT1 (AR) | Avoid fasting, protein restriction, emergency regimen | Stabilizing/preventative treatment | 5 | |
Urea cycle | Carbamoyl phosphate synthetase (CPS) deficiency | 237300 |
CPS1 (AR)
| Dietary protein restriction, arginine supplement, sodium benzoate, phenylbutyrate (Liver transplantation) | Stabilizing/preventative treatment (primary/targeting underlying pathophysiology) | 2b (4) |
Citrullinemia type I (ASS deficiency) | 215700 |
ASS1 (AR)
| Dietary protein restriction, arginine supplement, sodium benzoate, phenylbutyrate (Liver transplantation) | Stabilizing/preventative treatment (primary/targeting underlying pathophysiology) | 2b (4) | |
N-acetyl-glutamate synthetase deficiency | 237310 |
NAGS (AR)
| Dietary protein restriction, arginine supplement, sodium benzoate, phenylbutyrate (Liver transplantation) | Stabilizing/preventative treatment | 4 |
Blood tests | |||
---|---|---|---|
Acylcarnitine profiles (n = 3) | ● MCAD deficiency | ||
● SCAD deficiency | |||
● VLCAD deficiency | |||
Free-to-total serum/plasma carnitine (n = 1) | ● Carnitine palmitoyltransferase I deficiency | ||
Plasma Amino Acids (n = 10) | ● Argininemia | ● Hartnup disease | ● MTHFR Deficiency (&tHcy) |
● Argininosuccinate lyase deficiency | ● HHH syndrome | ● Ornithine transcarbamylase deficiency | |
● Citrullinemia type I | ● Maple syrup urine disease | ● Phenylketonuria (PKU) | |
● Citrullinemia, type II | |||
Plasma cholesterol (n = 1) | ● Cerebrotendinous xanthomatosis (CTX) | ||
Serum copper & ceruloplasmin (n = 2) | ● Menkes Disease (& urine deoxypyridinoline) | ||
● Wilson Disease (& urine copper) | |||
Urine tests
| |||
Urine creatine metabolites (n = 1) | ● GAMT deficiency | ||
Urine oligosaccharides (n = 1) | ● Fucosidosis | ||
Urine organic acids (n = 17) | ● 3-Methylglutaconic aciduria type 1 | ● Ethylmalonic encephalopathy (& ACP) | ● MHBD deficiency |
● 3-Methylcrotonyl-CoA carboxylase (MCC) deficiency (& ACP) | ● SSADH | ● HMG-CoA lyase deficiency | |
● β-Ketothiolase deficiency | ● Glutaric aciduria type I | ● mHMG-CoA synthase deficiency | |
● Cobalamin deficiencies (& PAA) | ● Holocarboxylase synthetase deficiency | ● Multiple acyl-CoA-dehydrogenase deficiency (MADD) | |
● Cystathionine β-synthase deficiency | ● Isovaleric academia | ● Propionic academia | |
● Methylmalonic academia | ● SCOT deficiency | ||
Urine purines & pyrimidines (n = 2) | ● Lesch-Nyhan syndrome | ||
● Molybdenum cofactor deficiency |
Biochemical category | Disease | Diagnostic test |
---|---|---|
Amino acids | PSAT deficiency | CSF amino acids (& PAA) |
PSPH deficiency (Serine deficiency) | CSF amino acids (& PAA) | |
Late onset non-ketotic hyperglycinemia | CSF AA (& Plasma AA) | |
PHGDH deficiency (Serine deficiency) | CSF AA (& Plasma AA) | |
Cerebral glucose transport | Blood brain-barrier glucose-transporter (GLUT1) defect | CSF glucose:plasma glucose ratio |
Creatine | Arginine: glycine amidinotransferase (AGAT) deficiency | GATM gene sequencing |
Creatine transporter deficiency | SLC6A8 gene sequencing | |
Lipids | Abetalipoproteinemia | CBC smear, stool samples, fasting lipid profile, MTTP gene analysis |
Lysosomal | Krabbe disease | WBC enzyme testing |
Metachromatic leucodystrophy (MLD) | Arylsulfatase-A enzyme activity | |
Niemann-Pick, type C | Filipin staining test (fibroblasts) & NPC1/NPC2 gene analyses | |
Mitochondria | Coenzyme Q10 deficiency | Coenzyme Q10 (fibroblasts) & gene(s) analysis |
MELAS | Mitochondrial DNA mutation testing | |
Pyruvate dehydrogenase deficiency | Blood & CSF lactate:pyruvate ratio (enzyme activity, gene(s) analysis) | |
Neurotransmission | Aromatic-L-amino-acid decarboxylase deficiency | CSF biogenic amines |
DHPR deficiency (biopterin deficiency) | CSF neurotransmitters & biopterin loading test | |
Dopamine transporter deficiency syndrome | CSF neurotransmitters | |
GTPCH1-deficient dopa-responsive dystonia | CSF neurotransmitters & biopterin/Phe loading test; clinical trial of L-dopamine, GTCPH gene analysis | |
PTPS deficiency (biopterin deficiency) | CSF neurotransmitters & biopterin loading test | |
Sepiapterin reductase deficiency | CSF neurotransmitters & biopterin/Phe loading test | |
Tyrosine hydroxylase deficiency | CSF neurotransmitters & TH gene analysis | |
Vesicular monoamine transporter 2 (VMAT2) | CSF monoamine metabolites | |
Urea cycle | Carbamoyl phosphate synthetase (CPS) deficiency | CPS gene analysis |
N-acetyl-glutamate synthetase deficiency | NAGS gene analysis | |
Vitamins/Co-factors | Biotinidase deficiency | Biotinidase enzyme activity |
Biotin-thiamine-responsive basal ganglia disease | SLC19A3 gene analysis | |
Cerebral folate deficiency syndrome | CSF tetrahydrofolate | |
Hypermanganesemia with dystonia, polycythemia, and cirrhosis | Whole-blood manganese concentrations, SLC30A10 gene analysis | |
Pyridoxamine 5’-phosphate oxidase deficiency | Plasma, CSF |